Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have received an average recommendation of "Buy" from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is $6.63.

TSHA has been the topic of several research analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Canaccord Genuity Group lifted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a report on Friday, November 15th. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. JMP Securities reissued a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in Taysha Gene Therapies in the third quarter worth $28,000. Principal Financial Group Inc. purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $48,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Taysha Gene Therapies by 79.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after purchasing an additional 17,446 shares during the period. Intech Investment Management LLC purchased a new stake in Taysha Gene Therapies during the third quarter worth about $85,000. Finally, Scientech Research LLC acquired a new position in Taysha Gene Therapies during the second quarter worth about $97,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Performance

Shares of TSHA traded up $0.01 during midday trading on Thursday, reaching $1.86. 1,513,496 shares of the stock were exchanged, compared to its average volume of 2,850,674. The company has a market capitalization of $381.19 million, a price-to-earnings ratio of 2.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The business's 50-day moving average price is $2.13 and its 200 day moving average price is $2.25.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.